KRAS and neoplasm: Hsiue, et al. [83] and Douglass, et al. [84] described the development of CD3 BsAbs in the form of single-chain diabodies (scDbs), which recognize mutant TP53 and KRAS short peptides presented by HLA on tumor cell surface.